Atomo Diagnostics Ltd. (AU:AT1) has released an update.
Atomo Diagnostics Ltd. reports robust growth with approximately 400k units of its HIV Self-Test sold in Q4 FY24, backed by the Australian Federal Government’s funding for HIV self-test procurement and the successful launch in UK’s Boots pharmacy chain. The company’s revenue for the quarter stood at $1.64 million, contributing to a year-to-date revenue of $4.09 million, with the quarter also ending debt-free and $3.69 million in cash. Atomo has experienced increased demand for its WHO prequalified self-test, with significant sales orders from global health partner Viatris and expanded visibility in both the Australian government-funded programs and UK retail markets.
For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.
